IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

Saved in:
Bibliographic Details
Title: IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Authors: Hack SP; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA., Spahn J; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA., Chen M; Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-sen University, Guangzhou, PR China., Cheng AL; National Taiwan University Cancer Center & National Taiwan University Hospital, Taipei, Taiwan., Kaseb A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Kudo M; Department of Gastroenterology & Hepatology, Kindai University School of Medicine, Osaka, Japan., Lee HC; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Yopp A; Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA., Chow P; Division of Surgical Oncology, National Cancer Centre, Singapore., Qin S; PLA Cancer Center, People's Liberation Army (PLA) 81 Hospital, Nanjing 210016, PR China.
Source: Future oncology (London, England) [Future Oncol] 2020 May; Vol. 16 (15), pp. 975-989. Date of Electronic Publication: 2020 Apr 30.
Publication Type: Clinical Trial Protocol; Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-8301
DOI:10.2217/fon-2020-0162